These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36006054)

  • 1. A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis.
    Bernthal NM; Healey JH; Palmerini E; Bauer S; Schreuder H; Leithner A; Martin-Broto J; Gouin F; Lopez-Bastida J; Gelderblom H; Staals EL; Burke ZD; Geiger EJ; Spierenburg G; Laeis P; Beyerlein E; Ye X; van de Sande M
    J Surg Oncol; 2022 Dec; 126(8):1520-1532. PubMed ID: 36006054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.
    Bernthal NM; Spierenburg G; Healey JH; Palmerini E; Bauer S; ; Gelderblom H; Staals EL; Lopez-Bastida J; Fronk EM; Ye X; Laeis P; van de Sande MAJ
    Orphanet J Rare Dis; 2021 Apr; 16(1):191. PubMed ID: 33926503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies.
    Palmerini E; Healey JH; Bernthal NM; Bauer S; Schreuder H; Leithner A; Martin-Broto J; Gouin F; Lopez-Bastida J; Gelderblom H; Staals EL; Mercier F; Laeis P; Ye X; van de Sande M
    Oncologist; 2023 Jun; 28(6):e425-e435. PubMed ID: 36869793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct extra-articular invasion patterns of diffuse pigmented villonodular synovitis/tenosynovial giant cell tumor in the knee joints.
    Kim DE; Kim JM; Lee BS; Kim NK; Lee SH; Bin SI
    Knee Surg Sports Traumatol Arthrosc; 2018 Nov; 26(11):3508-3514. PubMed ID: 29637236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
    Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
    Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
    [No Abstract]   [Full Text] [Related]  

  • 6. Active surveillance of diffuse-type tenosynovial giant cell tumors: A retrospective, multicenter cohort study.
    Spierenburg G; Staals EL; Palmerini E; Randall RL; Thorpe SW; Wunder JS; Ferguson PC; Verspoor FGM; Houdek MT; Bernthal NM; Schreuder BHWB; Gelderblom H; van de Sande MAJ; van der Heijden L
    Eur J Surg Oncol; 2024 Feb; 50(2):107953. PubMed ID: 38215550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of neoadjuvant pexidartinib with limb salvage surgery for diffuse tenosynovial giant cell tumor: A case report.
    Geiger EJ; Jensen AR; Singh AS; Nelson SD; Bernthal NM
    J Orthop Sci; 2024 Jan; 29(1):458-462. PubMed ID: 36402606
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment updates on tenosynovial giant cell tumor.
    Palmerini E; Staals EL
    Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of tenosynovial giant cell tumour of the foot and ankle.
    Spierenburg G; Lancaster ST; van der Heijden L; Mastboom MJL; Gelderblom H; Pratap S; van de Sande MAJ; Gibbons CLMH
    Bone Joint J; 2021 Apr; 103-B(4):788-794. PubMed ID: 33789469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Simple and Practical Clinical Classification for Tenosynovial Giant Cell Tumors of the Knee.
    Zheng K; Yu XC; Hu YC; Xu M; Zhang JY
    Orthop Surg; 2022 Feb; 14(2):290-297. PubMed ID: 34914180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study.
    Mastboom MJL; Palmerini E; Verspoor FGM; Rueten-Budde AJ; Stacchiotti S; Staals EL; Schaap GR; Jutte PC; Aston W; Gelderblom H; Leithner A; Dammerer D; Takeuchi A; Thio Q; Niu X; Wunder JS; ; van de Sande MAJ
    Lancet Oncol; 2019 Jun; 20(6):877-886. PubMed ID: 31029509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Image-guided, intensity-modulated radiotherapy for the treatment of diffuse-type tenosynovial giant cell tumor of the knee: Case report and review of the literature.
    Xiang X; Jiang W; Qiu C; Xiao N; Liang J
    Medicine (Baltimore); 2021 Jul; 100(28):e26659. PubMed ID: 34260572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function.
    Verspoor FGM; Mastboom MJL; Hannink G; van der Graaf WTA; van de Sande MAJ; Schreuder HWB
    Bone Joint J; 2019 Mar; 101-B(3):272-280. PubMed ID: 30813787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.
    Spierenburg G; Grimison P; Chevreau C; Stacchiotti S; Piperno-Neumann S; Le Cesne A; Ferraresi V; Italiano A; Duffaud F; Penel N; Metzger S; Chabaud S; van der Heijden L; Pérol D; van de Sande MAJ; Blay JY; Gelderblom H
    Eur J Cancer; 2022 Sep; 173():219-228. PubMed ID: 35932628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of Illness Associated with Tenosynovial Giant Cell Tumors.
    Burton TM; Ye X; Parker ED; Bancroft T; Healey J
    Clin Ther; 2018 Apr; 40(4):593-602.e1. PubMed ID: 29580718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour.
    Rebuzzi SE; Grassi M; Catalano F; Buscaglia M; Bertulli R; Satragno C; Belgioia L; Comandini D
    Anticancer Drugs; 2020 Jan; 31(1):80-84. PubMed ID: 31567307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
    Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
    Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
    Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
    Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.